Edition:
India

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

138.78USD
20 May 2019
Change (% chg)

$-1.42 (-1.01%)
Prev Close
$140.20
Open
$139.30
Day's High
$139.67
Day's Low
$138.50
Volume
314,038
Avg. Vol
607,271
52-wk High
$197.00
52-wk Low
$125.84

Latest Key Developments (Source: Significant Developments)

Allergan To Present Vraylar Data At The American Psychiatric Association 2019 Annual Meeting
Wednesday, 15 May 2019 

May 15 (Reuters) - Allergan plc ::ALLERGAN TO PRESENT VRAYLAR® (CARIPRAZINE) DATA AT THE AMERICAN PSYCHIATRIC ASSOCIATION (APA) 2019 ANNUAL MEETING HIGHLIGHTING CONTINUED COMMITMENT TO MENTAL HEALTH.ALLERGAN - FDA ACTION ON SUPPLEMENTAL NEW DRUG APPLICATION FOR VRAYLAR FOR TREATMENT OF BIPOLAR DEPRESSION IS EXPECTED IN FIRST HALF THIS YEAR.  Full Article

Allergan CEO Says Sense Of Urgency To Create Value Is High
Tuesday, 7 May 2019 

May 7 (Reuters) - Allergan plc ::ALLERGAN CEO SAYS SENSE OF URGENCY TO CREATE VALUE IS HIGH; BOARD IS ACTIVELY REVIEWING ALTERNATIVE AVENUES TO UNLOCK VALUE IN NEAR TERM: CONF. CALL.ALLERGAN SAYS Q1 SALES OF COOLSCULPTING IMPACTED BY CONSUMER DEMAND AND REDUCTION IN SYSTEM SALES IN THE US: CONF. CALL.ALLERGAN ESTIMATES ONLY 2 PERCENT OF PATIENTS ON NEW CLASS OF MIGRAINE DRUGS WERE SWITCHED FROM BOTOX AND COMBINATION USE IS LIMITED: CONF. CALL.ALLERGAN SAYS ANTICIPATING MID-MAY LOSS OF EXCLUSIVITY FOR RESTASIS.ALLERGAN CEO SAYS BOARD REMAINS OPEN-MINDED ABOUT SPLIT OF CO IF IT IS SOMETHING THAT CREATES LONG-TERM VALUE.  Full Article

Allergan PLC Posts Q1 GAAP Loss Per Share $7.25
Tuesday, 7 May 2019 

May 7 (Reuters) - Allergan plc ::ALLERGAN REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 GAAP LOSS PER SHARE $7.25.Q1 EARNINGS PER SHARE ESTIMATE $3.55 -- REFINITIV IBES DATA.Q1 NON-GAAP PERFORMANCE NET INCOME PER SHARE OF $3.79.RAISES FULL-YEAR 2019 GUIDANCE FOR NET REVENUE AND NON-GAAP PERFORMANCE NET INCOME PER SHARE.QTRLY TOTAL NET REVENUE $ 3,597.1 MILLION VERSUS $3,672.1 MILLION REPORTED LAST YEAR.Q1 GAAP NET REVENUE DRIVEN BY GROWTH IN TOP PROMOTED PRODUCTS INCLUDING BOTOX , VRAYLAR , JUVÉDERM COLLECTION OF FILLERS AND LO LOESTRIN.RESTASIS NET REVENUES IN Q1 OF 2019 WERE $231.7 MILLION, A DECREASE OF 9.4 PERCENT VERSUS PRIOR YEAR QUARTER.ALLERGAN RECORDED A GOODWILL IMPAIRMENT OF $2.47 BILLION IN THREE MONTHS ENDED MARCH 31, 2019.SEES FY GAAP REVENUE $15.125 BILLION - $15.425 BILLION.SEES FY NON GAAP REVENUE $15.100 BILLION - $15.400 BILLION.SEES FY GAAP LOSS PER SHARE GREATER THAN $5.70.SEES Q2 TOTAL NET REVENUES $3.875 BILLION - $4.025 BILLION.SEES Q2 NET INCOME PER SHARE $0.50 - $0.70.SEES FY NON GAAP EARNINGS PER SHARE GREATER THAN $16.55.FY2019 EARNINGS PER SHARE VIEW $16.44, REVENUE VIEW $15.20 BILLION -- REFINITIV IBES DATA.Q1 REVENUE VIEW $3.54 BILLION -- REFINITIV IBES DATA.SEES Q2 NON-GAAP NET INCOME PER SHARE $4.20 - $4.40.SEES Q2 NON-GAAP REVENUE $3.850 BILLION- $4.000 BILLION.QTRLY BOTOX NET REVENUE $868.4 MILLION VERSUS $817.3 MILLION.Q2 EARNINGS PER SHARE VIEW $4.20, REVENUE VIEW $3.87 BILLION -- REFINITIV IBES DATA.  Full Article

Allergan Says Shareholders Approved All Allergan Proposals
Wednesday, 1 May 2019 

May 1 (Reuters) - Allergan plc ::ALLERGAN ANNOUNCES RESULTS FROM THE 2019 ANNUAL GENERAL MEETING OF SHAREHOLDERS.ALLERGAN PLC - SHAREHOLDERS APPROVED ALL ALLERGAN PROPOSALS.ALLERGAN PLC - VOTED AGAINST SHAREHOLDER PROPOSAL CALLING FOR IMMEDIATE SEPARATION OF CHAIRMAN AND CEO ROLE.ALLERGAN PLC - SHAREHOLDERS REJECTED A SHAREHOLDER PROPOSAL TO IMMEDIATELY SEPARATE CHAIRMAN AND CEO.ALLERGAN PLC - SHAREHOLDERS ELECTED ALL OF 11 NOMINEES AS MEMBERS OF BOARD OF DIRECTORS, APPROVED AN ADVISORY RESOLUTION ON EXECUTIVE COMPENSATION.ALLERGAN PLC - APPROVED AN ADVISORY RESOLUTION ON EXECUTIVE COMPENSATION, COMMONLY REFERRED TO AS A "SAY ON PAY" VOTE, WITH 86.6 % OF VOTES CAST.ALLERGAN PLC - RENEWED AUTHORITY OF BOARD OF DIRECTORS TO ISSUE SHARES.ALLERGAN PLC - BASED ON TABULATION OF VOTES, 61.3 PERCENT OF SHAREHOLDERS VOTED AGAINST PROPOSAL TO IMMEDIATELY SEPARATE CHAIRMAN AND CEO.  Full Article

Allergan Acquires Envy Medical Inc
Tuesday, 26 Mar 2019 

March 26 (Reuters) - Allergan plc ::ALLERGAN ACQUIRES ENVY MEDICAL, INC., ADDING SKIN RESURFACING DERMALINFUSION SYSTEM TO BEST-IN-CLASS MEDICAL AESTHETICS PORTFOLIO.  Full Article

Allergan Says Believe Appaloosa Attempting To "Undermine Our CEO" And Pushing For A "Firesale" Of Co
Tuesday, 26 Mar 2019 

March 25 (Reuters) - Allergan plc ::ALLERGAN PLC - BELIEVE APPALOOSA ATTEMPTING TO "UNDERMINE OUR CEO" AND PUSHING FOR A "FIRESALE" OF CO.  Full Article

Allergan Adopts Policy For Chairman To Be Independent Member Of Board
Saturday, 23 Mar 2019 

March 22 (Reuters) - Allergan plc ::ALLERGAN - ADOPTED POLICY TO PROVIDE THAT CHAIRMAN OF BOARD SHALL BE AN INDEPENDENT MEMBER OF BOARD TO BE PHASED IN WITH NEXT LEADERSHIP TRANSITION..ALLERGAN - BOARD FORMED MERGERS AND ACQUISITIONS COMMITTEE TO PROVIDE FOCUSED OVERSIGHT ON MERGERS, ACQUISITIONS, DIVESTITURES, OTHER TRANSACTIONS.ALLERGAN - BOARD ADOPTED ENHANCEMENTS TO LEAD INDEPENDENT DIRECTOR ROLE, RESPONDING TO SHAREHOLDER INPUT AND FURTHER STRENGTHENING THE POSITION..ALLERGAN - CATHERINE KLEMA WILL NOT BE STANDING FOR RE-ELECTION TO BOARD AT 2019 ANNUAL GENERAL MEETING OF SHAREHOLDERS..ALLERGAN - THOMAS FREYMAN WILL BECOME CHAIR OF COMPENSATION COMMITTEE OF THE BOARD, EFFECTIVE AS OF KLEMA’S RETIREMENT FROM BOARD.  Full Article

Allergan Announces FDA Approval Of Avycaz For Pediatric Patients
Monday, 18 Mar 2019 

March 18 (Reuters) - Allergan plc ::ALLERGAN ANNOUNCES FDA APPROVAL OF AVYCAZ® (CEFTAZIDIME AND AVIBACTAM) FOR PEDIATRIC PATIENTS.ALLERGAN ANNOUNCES FDA APPROVAL OF AVYCAZ® (CEFTAZIDIME AND AVIBACTAM) FOR PEDIATRIC PATIENTS.ALLERGAN PLC - LABEL NOW INCLUDES NEW DATA ON USE OF AVYCAZ FOR TREATMENT OF CUTI AND CIAI IN PEDIATRIC PATIENTS 3 MONTHS OF AGE AND OLDER.ALLERGAN PLC - FROM FINDINGS, NO NEW SAFETY CONCERNS WERE IDENTIFIED IN PEDIATRIC PATIENTS..  Full Article

Appaloosa LP Sends Letter To Allergan About Resolution To Separate Roles Of Chairman, CEO
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Appaloosa LP::APPALOOSA LP SENDS LETTER TO ALLERGAN BOARD IN RESPONSE TO RESOLUTION TO SEPARATE ROLES OF CHAIRMAN AND CEO.APPALOOSA LP, IN LETTER TO ALLERGAN, SAYS SEEKS A MORE IMMEDIATE SEPARATION OF CHAIR AND CEO.SAYS WILL NOT WITHDRAW ITS ALLERGAN PROPOSALS FROM THIS YEAR’S PROXY STATEMENT.IF ALLERGAN BOARD "UNABLE OR UNWILLING" TO FIND SUITABLE REPLACEMENT, IT IS "FIDUCIARY OBLIGATION" TO EXPLORE OTHER OPTIONS, INCLUDING MERGER/SALE.BOB HUGIN WOULD HAVE BEEN A "CREDIBLE CANDIDATE" FOR ALLERGAN CHAIRMAN GIVEN "HIS STANDING IN THE INDUSTRY".  Full Article

Allergan PLC - Robert J. Hugin Appointed To Allergan Board Of Directors
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Allergan plc ::ROBERT J. HUGIN APPOINTED TO ALLERGAN BOARD OF DIRECTORS.ALLERGAN PLC - COMPANY TO RECOMMEND FOR A SHAREHOLDER PROPOSAL TO PHASE IN INDEPENDENT BOARD CHAIR AT NEXT LEADERSHIP TRANSITION.ALLERGAN PLC - HUGIN WAS FORMERLY CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF CELGENE CORPORATION.  Full Article

UPDATE 3-Allergan CEO says company is urgently looking at all options to boost share price

May 7 Allergan Plc Chief Executive Brent Saunders said on Tuesday that he and the board of directors were looking with a sense of urgency at all options to revive the Botox maker's falling share price, but a lack of specifics failed to boost investor sentiment.